Jitomira SN 25/5 Tablet (10 Tab)

Jitomira SN 25/5 Tablet Overview:

Jitomira SN 25/5 Tablet is a combination urological medication primarily used to treat the symptoms of an Overactive Bladder (OAB).

OAB is a condition characterized by a sudden, uncontrollable urge to urinate, often leading to increased urinary frequency throughout the day and night, as well as urge incontinence (accidental urine leakage).

To manage these disruptive symptoms, Jitomira SN 25/5 combines two complementary active components: Mirabegron (a beta-3 adrenergic agonist) and Solifenacin Succinate (an antimuscarinic agent). Together, these components deliver a synergistic effect that relaxes the hyperactive bladder muscles, minimizes sudden bladder spasms, and increases the volume of urine the bladder can comfortably hold.

By enhancing the stability of bladder muscle function, Jitomira SN 25/5 Tablet helps patients restore their urinary control, which in turn reduces the frequency of bathroom visits and lessens the anxiety associated with the risk of leakage.

Composition:

Each film coated bilayered tablet contains- Mirabegron (As Extended Release): 25 mg and Solifenacin Succinate: 5 mg.

Colour: Ferric Oxide Yellow & Titanium Dioxide.

Uses & Benefits of Jitomira SN 25/5 Tablet:

Jitomira SN 25/5 Tablet is prescribed for treating Overactive Bladder (OAB). The benefits include:

• Controls Urinary Urgency: It effectively calms the sudden, intense, and uncontrollable impulses to urinate.
• Decreases Urinary Frequency: Lowers the number of times you need to visit the bathroom throughout the day and night.
• Manages Urge Incontinence: It minimizes or completely prevents episodes of accidental urine leakage that typically follow a sudden, strong urge to void.

How Does Jitomira SN 25/5 Tablet Work:

The active ingredients in Jitomira SN 25/5 Tablet—Mirabegron and Solifenacin Succinate—belong to different classes of medication that work via distinct, complementary pathways to calm an overactive bladder:

Mirabegron, a Beta-3 Adrenergic Receptor Agonist, targets and activates specific beta-3 receptors located directly in the bladder's detrusor muscle. Stimulating these receptors causes the bladder muscle to become relaxed during the filling process (the storage phase). This relaxation significantly expands the bladder's physical capacity to hold urine comfortably.

Whereas, Solifenacin Succinate, an Anticholinergic agent, works by blocking cholinergic receptors on the bladder wall. Stopping the chemical signals that trigger involuntary muscle spasms prevents the sudden, premature bladder contractions that cause the frantic rush to the bathroom.

By combining these two mechanisms, Jitomira SN 25/5 deals with overactive bladder from two different ways simultaneously. Mirabegron maximizes the bladder's resting storage capacity, while Solifenacin suppresses unexpected spasms. Together, they provide a powerful, dual-action approach to restoring predictable bladder control and relaxation.

Dosage of Jitomira SN 25/5 Tablet:

• Usage Direction

Jitomira SN 25/5 Tablet should be taken strictly as per the doctor’s advice, following the prescribed dose and timing. Jitomira SN 25/5 Tablet should be swallowed whole with water and do not crush, chew or break the tablet. Take Jitomira SN 25/5 Tablet preferably at the same time each day. Do not stop or alter the dose of Jitomira SN 25/5 without consulting your doctor, as this may prevent you from achieving the desired outcome. If you are unsure about the administration procedures of this medication, consult with your doctor or pharmacist.

• Missed Dose

If you miss a dose of Jitomira SN 25/5 Tablet, take it as soon as you remember on the same day. But, if it is almost time for your next scheduled dose, skip the one you missed and continue following your regular dosing schedule. Do not attempt to take two doses if you have forgotten one. If you often forget to take your medication, consult with your doctor to re-evaluate your dosing schedule. Frequently missing doses could lead to undesired outcomes.

You can set reminders on your smartphone, keep drug organizer boxes, or use other audio-visual technologies to prevent missing a dose.

• Overdose

If you accidentally take Jitomira SN 25/5 Tablet more than your prescribed dose, seek immediate medical attention or go to the nearest hospital for further advice. Symptoms of overdose may include severe dizziness, severe dry mouth, blurred vision, or an abnormally fast heart rate.

Contraindications of Jitomira SN 25/5 Tablet:

Do not take Jitomira SN 25/5 Tablet if you have a known hypersensitivity or allergy to Mirabegron, Solifenacin, or any other components of this medicine.

It is contraindicated in individuals suffering from urinary retention, where the bladder is unable to empty properly, as well as those with gastric retention or severe gastrointestinal obstructive disorders that slow down stomach emptying.

Furthermore, due to the specific mechanism of its active components, the medication must be avoided by patients with uncontrolled severe hypertension, as Mirabegron can further elevate blood pressure, and by individuals with poorly managed narrow-angle glaucoma.

Finally, patients experiencing severe hepatic or renal impairment should not take this medication, particularly if they are concurrently taking strong CYP3A4 inhibitors.

Precautions & Warnings of Jitomira SN 25/5 Tablet:

Before taking Jitomira SN 25/5 Tablet, it is crucial to consult a healthcare provider and discuss your complete medical history. One of the active ingredients, Mirabegron, can elevate blood pressure; regular blood pressure check-ups are essential during the therapy.

Additionally, it must be used with extreme caution if you have a bladder blockage or difficulty urinating, as the smooth muscle relaxation caused by the drug can increase the risk of acute urinary retention.

Patients with liver or kidney disease must also inform their doctor before use, as hepatic and renal impairments require careful dosage adjustments.

Furthermore, because Solifenacin can significantly prolong the QT interval, patients should consult their doctor if they have a history of QT prolongation or are taking concurrent medications that affect heart rhythms.

Moreover, some patients may experience rare allergic reactions (angioedema) associated with severe swelling of the face, lips, tongue, or throat, or any difficulty breathing, the medication must be discontinued immediately, and urgent medical care must be sought.

Side Effects of Jitomira SN 25/5 Tablet:

While Jitomira SN 25/5 Tablet is generally well-tolerated, it may cause various side effects, the majority of which are mild to moderate and typically diminish as the body adjusts to the medication. The most common symptoms include dry mouth, constipation, urinary tract infection (UTI), headache, and elevated blood pressure.

Some patients may also experience secondary effects such as blurred vision, dizziness, dry eyes, generalized fatigue, mild abdominal pain, or tachycardia (an abnormally fast heart rate).

Conversely, serious side effects are rare but require immediate medical attention. Patients should seek urgent care if they experience a severe or sudden spike in blood pressure, an inability to empty the bladder (acute urinary retention), or symptoms indicative of angioedema—a life-threatening allergic reaction characterized by rapid swelling of the face, lips, tongue, or throat, or difficulty breathing.

Safety Related Concerns of Jitomira SN 25/5 Tablet:

• Pregnancy

Jitomira SN 25/5 Tablet should be used with caution during pregnancy, unless clearly needed and prescribed by a doctor, as limited data exist regarding its safety in pregnant women. If you are pregnant or planning to become pregnant, talk to your doctor before taking this medication to weigh the benefits against potential risks to the developing baby.

• Breastfeeding

It is better to avoid the use of the Jitomira SN 25/5 Tablet while breastfeeding, since it is unknown whether the active ingredient could pass into the breast milk and affect the breastfed child. Therefore, consulting with your doctor before taking Jitomira SN 25/5 Tablet is crucial.

• Alcohol

There is no known direct pharmacological interaction between alcohol and Jitomira SN 25/5 Tablet. However, healthcare providers generally advise limiting or avoiding alcohol consumption during treatment. Alcohol can worsen bladder irritation, increase urinary frequency, and amplify dizziness or drowsiness caused by the medication.

• Food Interactions

Jitomira SN 25/5 Tablet can be taken with or without food, as directed by your healthcare professional. While there are no direct interactions between this medication and specific food items, certain dietary habits can independently exacerbate bladder hyperactivity.

Patients may be advised to limit or avoid known bladder irritants, including excessive caffeine, alcohol, carbonated beverages, artificial sweeteners, and highly acidic items, such as citrus juices or tomato-based products.

Restricting these dietary triggers works synergistically with the medication to minimize unexpected bladder spasms, ultimately enhancing the overall effectiveness of the treatment and accelerating improvements in bladder control.

• Drug Interactions

Jitomira SN 25/5 Tablet can interact with various medications, either by changing their effectiveness or increasing the risk of toxicity. It is crucial to inform your healthcare provider that taking the medication along with strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) can significantly increase levels of Solifenacin in the body. In addition, concurrent use of other anticholinergic medicines may increase the likelihood and severity of side effects such as dry mouth, constipation, and difficulty emptying the bladder. Additionally, because Mirabegron is a moderate CYP2D6 inhibitor, it can elevate the blood concentrations of drugs metabolized by this enzyme, including metoprolol and certain antidepressants. Patients taking medicines with a narrow therapeutic range, such as digoxin or warfarin, should be monitored carefully during treatment, as dosage adjustments may be necessary to maintain their safety and effectiveness.

Always inform your healthcare provider and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, minerals, and herbal supplements, to avoid potential interactions.

• Using Machinery & Driving

Jitomira SN 25/5 Tablet may cause blurred vision, drowsiness, or dizziness. Avoid driving, operating machinery, or performing tasks that require alertness until you understand how this medicine affects your concentration and coordination.

Storage of Jitomira SN 25/5 Tablet:

Store at a temperature not exceeding 25°C.

Avoid using it after the expiry date, printed on the packaging. Dispose of expired or unused medication properly; do not throw it away casually. Keep the medicine out of reach of children.

Additional Information:

• Regular pelvic floor exercises can help improve bladder control and reduce sudden urges to urinate.
• Try to delay urination by 10–15 minutes when you feel the urge, as this can help train your bladder to hold urine longer.
• Avoid or limit bladder irritants such as caffeine, alcohol, spicy foods, artificial sweeteners, tomatoes, and citrus fruits.
• Reduce fluid intake 2–3 hours before bedtime to help prevent frequent nighttime urination.
• Do not suddenly stop your medication unless your doctor specifically tells you to.
• Do not share your medicine with someone else having the same symptoms as you, as the drug requires a prescription.

Frequently Asked Questions (FAQs):

Q. What is Jitomira SN 25/5 Tablet used for?

A. Jitomira SN 25/5 Tablet is a prescription medicine used for the treatment of Overactive Bladder (OAB). It effectively relieves the core symptoms of OAB, including sudden urinary urgency, frequent daytime and nighttime bathroom visits, and accidental urine leakage (urge incontinence).

Q. How does Jitomira SN 25/5 work?

A. Jitomira SN 25/5 Tablet uses a dual-action approach to calm an overactive bladder. Mirabegron relaxes the bladder muscle during the storage phase, expanding its capacity to hold urine. Simultaneously, Solifenacin blocks the chemical signals that trigger involuntary bladder spasms, preventing sudden, premature contractions and reducing the urgent rush to the bathroom.

Q. Why does this medication cause a dry mouth, and how can I manage it?

A. The Solifenacin component in Jitomira SN 25/5 blocks acetylcholine, a chemical messenger that naturally triggers saliva production, leading to a dry mouth. To manage this common side effect, you can sip water frequently throughout the day, suck on ice chips, or chew sugar-free gum to safely stimulate saliva flow.

Q. Will Jitomira SN 25/5 cure my overactive bladder permanently?

A. No, Jitomira SN 25/5 does not permanently cure the underlying condition. It effectively manages and controls the symptoms of an overactive bladder only while you are actively taking it. If the medication is discontinued, your symptoms are highly likely to return. Always consult your doctor before stopping the medication.

Q. Is this combination drug more effective than a single-therapy drug?

A. Yes, Clinical research indicates that the combination of Mirabegron and Solifenacin generally provides better control of overactive bladder symptoms than treatment with either medicine on its own. Because they target two different biological pathways, they work synergistically to provide greater relief from sudden leaks, maximize the bladder's holding capacity, and reduce the total number of daily bathroom visits. Furthermore, using this combination often provides superior symptom control compared to simply increasing the dose of a single drug, without drastically increasing side effects like severe dry mouth or constipation.

Reference:

Jito Mira SN- Patient Information Leaflet